| Title |
Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2015
|
| DOI | 10.2147/dddt.s82098 |
| Pubmed ID | |
| Authors |
Moo-Yong Rhee, Sang Hong Baek, Weon Kim, Chang Gyu Park, Seung Woo Park, Byung-Hee Oh, Sang-Hyun Kim, Jae-Joong Kim, Joon-Han Shin, Byung-Su Yoo, Se-Joong Rim, Jong-Won Ha, Joon Hyung Doh, Youngkeun Ahn, Jei Keon Chae, Jeong Bae Park, Soon-Kil Kim, Cheol Ho Kim |
| Abstract |
The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg. Patients with sitting diastolic blood pressure (siDBP) ≥90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was ≥90 mmHg. Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88±8.10 mmHg vs 3.38±7.33, P=0.0008), and the effect persisted at Week 8 (8.67±9.39 mmHg vs 5.02±8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50±13.76 mmHg vs 5.75±12.18 mmHg, P=0.0069 and, at Week 8, 13.45±15.15 mmHg vs 6.84±13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP <90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, P=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups. The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 15% |
| Student > Doctoral Student | 3 | 12% |
| Student > Bachelor | 2 | 8% |
| Student > Ph. D. Student | 2 | 8% |
| Professor | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 11 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Chemistry | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 13 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2016.
All research outputs
#8,535,684
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#641
of 2,268 outputs
Outputs of similar age
#97,060
of 281,412 outputs
Outputs of similar age from Drug Design, Development and Therapy
#36
of 126 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,412 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 126 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.